Mounjaro®
Starting from £179.99/mo
Start journey Learn moreChoosing the right injection site can make a real difference to how you feel after each weekly dose of Mounjaro. The three licensed sites are the abdomen, the front of the thigh, and the outer upper arm, and rotating between them consistently is the single most practical step you can take to reduce injection-site reactions and support comfortable ongoing treatment. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber assesses suitability before treatment begins, and how you use the pen is part of that clinical conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The abdomen, thigh and outer upper arm are the sites confirmed in the Mounjaro SmPC. Most people find the abdomen the easiest to reach independently, and it offers the most surface area for rotation. Aim for the fatty tissue around the navel, staying at least a couple of centimetres away from the navel itself and clear of the waistband area. The front and outer thigh works well if the abdomen is sore or bruised, and is a reliable choice for self-injection. The upper arm is a viable third option, though it typically requires a second person to administer the dose safely.
Absorption rate can vary slightly between sites, but the licensed guidance does not rank one site as clinically superior for tolerability. What matters far more is consistency within a rotation pattern. A question our prescribers hear most weeks is whether the injection site changes how much nausea a patient experiences. The honest answer is that gastrointestinal effects are driven by the medicine itself, not the needle's location. Site choice mainly influences local reactions: bruising, tenderness, or the small lumps (lipohypertrophy) that build up when the same spot is used repeatedly. If you are using the KwikPen specifically, you can read more about the side effects associated with the Mounjaro KwikPen and how they tend to behave over time, alongside the broader injection side effects of Mounjaro.
Clean the skin with an alcohol swab and let it dry fully before injecting. Medical-grade alcohol swabs make this straightforward. Pinching the skin slightly, inserting the needle at the angle described in the Patient Information Leaflet, and holding the pen in place for the full count after activation all reduce the chance of incomplete delivery or localised irritation.
Rotation matters more than most people expect. Repeatedly injecting the same small area causes the fatty tissue beneath the skin to thicken over time. That thickening, called lipohypertrophy, can slow how reliably the medicine absorbs and make the area more sensitive to future injections.
A simple approach: divide each site into a grid of zones and move to the next zone each week. Many people find it helpful to keep a short note of where they injected last, at least while they are establishing the habit. Once rotation becomes routine it takes very little thought. The best injection site for Mounjaro is effectively whichever one you have not used recently in a consistent pattern.
Avoid injecting through clothing, into skin that is bruised, tender, scarred or affected by rashes, and into the same spot you used the previous week. Letting the pen reach room temperature for a few minutes before use is also worth doing; cold solution from the fridge can sting more on entry. The exact storage and handling guidance, including how long the pen may be kept out of the fridge, is set out in the Patient Information Leaflet and on the Mounjaro SmPC on the eMC.
Most people on Mounjaro experience some gastrointestinal symptoms at the start of treatment or after a dose increase. Nausea is the most common, followed by loose stools, indigestion and fatigue. These effects are described in detail on the full side-effect profile for Mounjaro injections. They are not caused by injection technique and they generally ease as the body adjusts, often within the first few weeks at each dose level.
Some symptoms, though, need prompt clinical attention rather than watchful waiting. Seek medical help the same day if you develop severe stomach pain that does not pass and radiates toward your back, with or without vomiting. This can be a sign of pancreatitis, which the MHRA highlighted in a Drug Safety Update for GLP-1 medicines as an infrequent but serious risk. Similarly, symptoms suggestive of a gallbladder problem, such as sharp upper-right abdominal pain, should not be left until your next scheduled review.
Signs of a severe allergic reaction require emergency care: swelling of the face or throat, difficulty breathing, or a rapid-onset rash. Injection-site reactions that spread, become very warm or show signs of infection rather than settling within a day or two should be reviewed by a clinician. If you are unsure whether what you are experiencing is expected, the safest course is to contact your prescriber. Our aftercare team is available seven days a week for patients who need guidance between scheduled reviews. You can also find broader reassurance in what to expect from Mounjaro side effects overall.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.